Genexine

R&D History We will prove our expertise through ceaseless efforts

2017 ~ 2022

2022
· Moved into Bio Innovation Park (Magok)
2021
· Technology transfer to KGBio (Indonesia) (GX-I7)
2020
· Technology transfer to Genenbio (GX-P1, GX-P10)
2019
· GX-188E, Phase 2 clinical trial and entry
2018
· Korean clinical trial 1b/2a approval for concurrent administration of immune checkpoint inhibitors for triple-negative breast cancer patients
· US Roche, NIT signed a contract for joint clinical development of HyLeukin-7&immune checkpoint inhibitor combination therapy
2017
· I-Mab (merged 3rd Venture and Tasgen) Technology transfer (GX-I7)

2010 ~ 2016

2016
· Technology transfer to Chemowanbang (GX-E4)
2015
· Technology transfer to Tasgen (Tasly and J.V.) (H9, G6, G3)
· Technology transfer to NIT (GX-188E, GX-I7)
2014
· igned a biopharmaceutical development agreement with Hebang
2013
· Technology transfer to ILKOGEN (ILKO and J.V) (GX-G3)
2012
· Technology transfer to Handok (GX-H9)

1999 ~ 2009

2009
· Listed on the KOSDAQ by special technology
2008
· Technology transfer to Ildong Pharmaceutical Company (GX-G6)
2006
· hyFc development and joint R&D with Dong-A Pharmaceutical Company
2005
· Started phase 1 clinical trial for hepatitis B treatment
1999
· Established Genexine Co., Ltd. (Gene + Vaccine)